Skip to main content

Table 1 Characteristics of 80 genotype 1-infected chronic hepatitis C patients treated with pegylated interferon alpha 2b plus ribavirin combination, classified by the treatment response

From: Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment

Characteristics

Total

SVR

Non-SVR

P value

 

No. = 80

No. = 39

No. = 41

 

Male No. (%)

36 (45.0)

17 (43.6)

19 (46.3)

0.9821

Age (years)

57.4 ± 9.8

54.8 ± 9.3

59.8 ± 9.7

0.0133

Body Mass Index (kg/m2)

23.0 ± 3.1

23.1 ± 3.0

23.6 ± 3.4

0.7821

Alanine aminotransferase (IU/L)

89.9 ± 65.4

93.2 ± 62.8

86.5 ± 65.7

0.7832

γ-glutamyltranspeptidase (IU/L)

59.2 ± 54.0

41.2 ± 34.2

77.3 ± 33.1

0.0548

Albumin (g/dL)

4.2 ± 0.4

4.2 ± 0.4

4.0 ± 0.4

0.7105

White blood cell count (109/L)

5.6 ± 1.4

5.3 ± 1.4

5.8 ± 1.7

0.4666

Hemoglobin (g/L)

131 ± 14

133 ± 14

129 ± 14

0.2310

Platelet count (109/L)

161 ± 51

167 ± 45

156 ± 55

0.1576

Creatinine (mg/dL)

0.71 ± 0.14

0.69 ± 0.16

0.70 ± 0.15

0.3376

Creatinine clearance (mL/min)

98.8 ± 27.6

100.2 ± 28.7

99.3 ± 32.3

0.4102

Histological cirrhosis No. (%)

6 (7.5)

2 (5.1)

4 (9.7)

0.6758

  1. HCV, hepatitis C virus
  2. Data is shown as the mean ± standard deviation.
  3. SVR means a sustained virological response, which is defined as serum HCV RNA undetectable at 24 weeks after the end of treatment.